Highlights of adjuvant therapy for NSCLC: T drug became the first and only approved adjuvant immune drug K drug Phase III clinical data released

Recently, many new advances have been made in the field of adjuvant therapy for non-small cell lung cancer (NSCLC)

On March 16, the China National Medical Products Administration officially approved Roche's innovative tumor immunotherapy drug atezolizumab (trade name: Tecentriq®) as a single drug for the detection of tumor cells with an assessment of ≥1% ( TC) Adjuvant therapy for patients with stage II-IIIA non-small cell lung cancer with positive PD-L1 staining, surgical resection, and platinum-based chemotherapy[1]

The results of the IMpower010 study showed that in patients with stage II-IIIA NSCLC whose tumors expressed PD-L1 ≥1%, atezolizumab was used as adjuvant therapy after surgery and chemotherapy, compared with the current best treatment.

In October last year, Tecentriq became the first immuno-oncology drug approved by the US FDA for the adjuvant treatment of early-stage NSCLC [3]

Recently, Merck announced the specific data of Keytruda in the adjuvant (postoperative) treatment of early-stage lung cancer

The Phase 3 KEYNOTE-091 trial met one of the co-primary endpoints of disease-free survival (DFS) in the entire patient population regardless of tumor PD-L1 expression status, according to data presented at the European Society of Medical Oncology (ESMO) plenary meeting.

In the data published by Merck, Keytruda had a disease-free survival benefit of 18% in patients with PD-L1 expression ≥50% (HR=0.

How does Keytruda perform in subgroups of patients, especially those with stage IB or PD-L1-negative disease

But so far, only "T" drugs have been officially approved for supplementary indications in China

Reference source

1.

3.

5.

6.

7.